What review of systems should be performed before initiating hormone replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Review of Systems Before Initiating Hormone Replacement Therapy

Before initiating HRT, perform a focused clinical assessment including measurement of weight, blood pressure, gynecologic examination with breast palpation, and screening for cardiovascular risk factors, VTE history, undiagnosed vaginal bleeding, and personal/family history of breast cancer. 1, 2

Essential Pre-Treatment Evaluation

Mandatory Clinical Assessment

  • Cardiovascular screening: Blood pressure measurement and assessment of cardiovascular risk factors are essential 1
  • Breast evaluation: Clinical breast examination and mammography (particularly important as estrogen can promote growth of subclinical breast cancer) 1, 3
  • Gynecologic examination: To exclude undiagnosed abnormal vaginal bleeding, suspected or active endometrial cancer 1
  • Weight and BMI: Document baseline, as BMI >30 kg/m² influences route selection 4, 1

Critical History Elements

Absolute contraindications to identify:

  • Personal history of breast cancer 1, 2
  • Undiagnosed abnormal vaginal bleeding 1
  • Active or suspected endometrial cancer 1
  • History of VTE or thrombophilia (requires hematology consultation before considering transdermal HRT) 4, 1

Conditions requiring route/regimen modification (NOT contraindications):

  • Migraine with aura: Use transdermal estradiol preferentially 4
  • Hypertension: Use transdermal estradiol 4, 2
  • Obesity (BMI >30): Use transdermal estradiol 4, 1
  • Endometriosis: Can use HRT but combined estrogen/progestogen preferred to reduce reactivation risk 4, 2
  • Fibromas: Not a contraindication 4

Laboratory and Imaging

No routine laboratory monitoring is required before initiating HRT in most women 1, 2. However, specific testing should be prompted by clinical concerns:

  • Bone density (DEXA): Consider 1-2 years after surgical menopause if additional risk factors for osteoporosis exist, NOT routinely before starting 1
  • Lipid profile and inflammatory markers: Only if cardiovascular risk assessment indicates 5
  • Hormone levels (FSH, estradiol): Generally not helpful for treatment decisions 1
  • Endometrial biopsy: NOT cost-effective or necessary in women without abnormal bleeding 3

Common Pitfalls to Avoid

  1. Over-medicalization: Do not subject women to unnecessary screening procedures that may inhibit access to HRT 3
  2. Routine endometrial monitoring: It is NOT necessary to routinely monitor endometrial thickness while using HRT 1
  3. Serum hormone monitoring: Hormone levels are generally not helpful in making treatment decisions 1
  4. Delaying treatment for extensive testing: History and physical examination with blood pressure measurement are sufficient to determine if contraindications exist 3

Route Selection Based on Risk Factors

Transdermal estradiol is preferred for:

  • BMI >30 kg/m² 4, 1
  • Hypertension 4
  • Migraine with aura 4
  • History of VTE (after hematology consultation) 4, 1
  • Increased VTE risk (transdermal has similar risk to baseline population, while oral increases VTE risk especially in first year) 1

Combined estrogen-progestogen required for:

  • All women with intact uterus to protect endometrium 1, 2

Follow-Up Monitoring Schedule

After initiating HRT 1, 2, 1:

  • 3-month review: Confirm acceptability, efficacy, and adjust if needed
  • Annual clinical examination: Including gynecologic exam, breast palpation, weight, and blood pressure measurement 4
  • Investigations only if prompted by specific symptoms (e.g., unexpected bleeding) 1, 2
  • Cardiovascular risk factor evaluation at each visit 1

The evidence strongly supports that extensive pre-treatment testing beyond history, physical examination, blood pressure, and breast screening is not cost-effective and creates unnecessary barriers to appropriate HRT use 3.

Related Questions

What is the recommended monitoring schedule and assessments for postmenopausal hormone replacement therapy, including baseline evaluation, follow‑up visits, and long‑term laboratory and clinical surveillance?
What baseline laboratory tests should be obtained before initiating hormone replacement therapy in women?
What baseline laboratory tests should be obtained before initiating hormone replacement therapy?
Should a woman who has had her cervix removed receive both estradiol and progesterone, and does the need depend on whether her uterus is intact?
In a 51-year-old woman with a total hysterectomy and prior hormone replacement therapy (HRT), is a mammogram performed 14 months ago acceptable as a baseline before restarting estrogen therapy?
What are the target serum testosterone trough levels, required laboratory tests, and monitoring schedule for women undergoing testosterone pellet therapy?
What is the optimal blood glucose target and management strategy for patients with necrotizing fasciitis?
For a patient with intellectual disability and early dementia, what is the recommended starting dose and which is preferred, donepezil (Aricept) or memantine (Namenda)?
Should the cardiac risks of quetiapine (Seroquel) and trazodone affect the plan to start donepezil, and how closely should cardiac safety be monitored?
In a hypertensive adult patient on losartan with well‑controlled blood pressure who has had 2 days of vomiting, dizziness/vertigo, and tinnitus, what are the possible etiologies and recommended next steps in management?
A child who missed the 2‑month well‑child visit and was seen at 3 months can be scheduled for the 4‑month well‑child visit in one month?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.